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ABSTRACT
The activity of dalbavancin, a new semi-synthetic lipoglycopeptide antibiotic, was evaluated in
comparison with other antibacterial agents against 1229 Gram-positive organisms collected from
medical centres in Latin America. Dalbavancin was the most potent compound tested against isolates
of Staphylococcus aureus (MIC50, 0.06 mg ⁄L) and coagulase-negative staphylococci (MIC50, 0.03 mg ⁄L),
independently of methicillin susceptibility. Dalbavancin inhibited all Streptococcus pneumoniae isolates
at £ 0.06 mg ⁄L. Dalbavancin also demonstrated excellent activity against b-haemolytic
(MIC50, £ 0.008 mg ⁄L) and viridans group (MIC50, 0.016 mg ⁄L) streptococci. All vancomycin-suscept-
ible Enterococcus spp. isolates were inhibited by dalbavancin at £ 0.25 mg ⁄L, but some vancomycin-
resistant Enterococcus spp. isolates were only inhibited by dalbavancin levels of ‡ 8 mg ⁄L. Dalbavancin
exhibited excellent activity against isolates of Corynebacterium spp. and Listeria spp. Dalbavancin may
provide an important therapeutic option for Gram-positive infections, excluding those caused by
enterococci with VanA-type resistance.
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INTRODUCTION
Staphylococci are major causes of both commu-
nity-and hospital-acquired infections. Since meth-
icillin (oxacillin) resistance was first reported in
1961, rates of resistance to penicillinase-resistant
penicillins among isolates of Staphylococcus aureus
and coagulase-negative staphylococci have
increased greatly worldwide [1,2]. In many Latin
American hospitals, methicillin-resistant S. aureus
(MRSA) strains have become endemic and are
increasingly resistant to many other antimicrobial
agents [3]. Data from the SENTRY Antimicrobial
Surveillance Program have demonstrated that
methicillin resistance rates vary widely, from
8.6% to 45.3%, among S. aureus isolates collected
from different Latin American medical centres
[2].
Glycopeptides such as vancomycin and tei-
coplanin have been the drugs of choice for
treatment of methicillin-resistant staphylococcal
infections [2]. These agents have also been used
successfully as therapeutic agents against life-
threatening Enterococcus spp. and cephalosporin-
resistant Streptococcus pneumoniae infections [4,5].
However, the emergence of vancomycin resist-
ance among enterococci initiated the glycopeptide
resistance era. Resistance, including high-level
glycopeptide resistance, is now quite common in
enterococci. Reduced susceptibility to vancomy-
cin in isolates of S. aureus occurs infrequently, and
rare instances of high-level vancomycin resistance
in S. aureus have also been detected following
acquisition of the vanA operon [6,7]. Compounds
such as quinupristin–dalfopristin and linezolid
have been developed to overcome emerging
glycopeptide resistance. However, resistance to
Corresponding author and reprint requests: A. C. Gales,
Division of Infectious Diseases, Universidade Federal de Sao,
Paulo, Sao Paulo, Brazil
E-mail: galesac@aol.com
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
these agents has also been detected in Enterococcus
faecium and S. aureus [8,9]. This fact has accentu-
ated the need for additional new antimicrobial
compounds.
Dalbavancin is a novel semi-synthetic amide
derivative of the lipoglycopeptide A40926. Like
other glycopeptides, it interferes with bacterial
cell wall biosynthesis [10]. Dalbavancin has a
wide spectrum of activity against Gram-positive
organisms, including both aerobic and anaerobic
species [10–12]. In addition, it is extremely potent
against multiresistant bacteria, including MRSA,
coagulase-negative staphylococci and penicillin-
resistant Strep. pneumoniae. Dalbavancin has also
demonstrated excellent activity in several animal
models of infection, including acute septicaemia
in mice, lobar pneumonia in rats, and endocardi-
tis in rats and rabbits [10,13]. As it has a long
elimination half-life in humans (c. 7 days), a
dosage interval of 1 week has been tested for
treatment of complicated skin and soft tissue
infections [14]. To evaluate the potential efficacy
of dalbavancin against Gram-positive organisms
isolated in Latin America, the present study
determined its comparative in-vitro activity
against 1229 clinical isolates collected recently
from this geographical region.
MATERIALS AND METHODS
Bacterial strains
In total, 1229 Gram-positive organisms, collected from ten
Latin American medical centres between January and Decem-
ber 2003, were studied. The species distribution was as
follows: S. aureus, 536 isolates; coagulase-negative staphylo-
cocci, 251; Strep. pneumoniae, 208; Enterococcus spp., 157;
b-haemolytic streptococci, 53; viridans group streptococci, 13;
Listeria spp., 6; Corynebacterium spp., 3; and Micrococcus spp., 2.
Organisms were isolated from diverse body sites of hospital-
ised patients, but only a single isolate ⁄patient was included in
this study. The participating medical centres were located in
nine cities in five countries: Brası´lia, Floriano´polis, Sa˜o Paulo
and Porto Alegre in Brazil; Buenos Aires and San Isidro in
Argentina; Santiago in Chile (two sites); Mexico City in
Mexico; and Caracas in Venezuela.
Susceptibility testing
Antimicrobial susceptibility testing was performed using the
NCCLS reference broth microdilution method [15]. Dalba-
vancin powder was obtained from Vicuron Pharmaceuticals
(King of Prussia, PA, USA). Powders of comparator antimi-
crobial agents were provided by the respective manufacturers
or purchased from Sigma Chemicals (St Louis, MO, USA).
Validated dry-form broth microdilution trays were prepared
by TREK Diagnostics (Cleveland, OH, USA). Susceptibility
testing results were interpreted according to NCCLS criteria,
except for dalbavancin, for which susceptibility and resistance
breakpoints have not yet been established [16]. Quality
control was performed by testing Enterococcus faecalis ATCC
29212, S. aureus ATCC 29213, and Strep. pneumoniae ATCC
49619.
RESULTS
The in-vitro activities of dalbavancin, compared
to those of 11 other antimicrobial agents, against
787 staphylococcal isolates, 274 streptococcal iso-
lates, 157 enterococcal isolates and 11 uncommon
Gram-positive organisms isolated from patients
in Latin American medical centres are shown in
Table 1. Against S. aureus, dalbavancin (MIC50,
0.06 mg ⁄L) was, respectively, 32-, 16- and eight-
fold more potent than linezolid (MIC50, 2 mg ⁄L),
vancomycin (MIC50, 1 mg ⁄L) and quinupristin–
dalfopristin (MIC50, 0.5 mg ⁄L). Dalbavancin
inhibited all S. aureus isolates at £ 0.25 mg ⁄L. No
S. aureus isolate was resistant to vancomycin,
teicoplanin, linezolid or quinupristin–dalfopris-
tin. Among coagulase-negative (CoNS) isolates,
dalbavancin (MIC50, 0.03 mg ⁄L) was 64-fold more
potent than teicoplanin, 32-fold more potent than
vancomycin and linezolid, and eight-fold more
potent than quinupristin–dalfopristin. Only
vancomycin and linezolid inhibited 100% of
CoNS isolates at the NCCLS susceptibility break-
points [16]. Among staphylococci, 26.7% of S.
aureus isolates and 76.9% of CoNS isolates were
methicillin-resistant. In addition, 2.0% of CoNS
isolates were resistant to teicoplanin. No differ-
ence in dalbavancin activity was observed be-
tween oxacillin-susceptible and oxacillin-resistant
S. aureus (Table 2). However, a slight trend
toward higher dalbavancin MICs was observed
among oxacillin-resistant CoNS isolates; thus,
100% of oxacillin-susceptible CoNS isolates were
inhibited by dalbavancin 0.12 mg ⁄L, compared to
only 92.2% of oxacillin-resistant CoNS isolates.
Against Strep. pneumoniae, dalbavancin (MIC50,
0.016 mg ⁄L) was 16- and 32-fold more potent than
vancomycin and linezolid, respectively. Among
Strep. pneumoniae isolates, the lowest susceptibil-
ity rate was observed for trimethoprim–sulpha-
methoxazole (57.7%), followed by penicillin
(73.1%), erythromycin (84.5%) and tetracycline
(86.1%). Dalbavancin inhibited all pneumococcal
isolates at £ 0.06 mg ⁄L, regardless of the degree of
penicillin susceptibility. Indeed, all penicillin-
resistant Strep. pneumoniae isolates (0.016 mg ⁄L)
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Table 1. In-vitro activities of dalbavancin, compared to those of 11 other antimicrobial agents, against 787 staphylococcal
isolates, 274 streptococcal isolates and 157 enterococcal isolates from patients in Latin American medical centres (2003)
Organism ⁄ antimicrobial (no. tested)
MIC (mg/L) Percentage by categorya
Range 50% 90% Susceptible Resistant
Staphylococcus aureus (536)
Dalbavancin £ 0.008–0.25 0.06 0.06 –a –
Teicoplanin £ 2–8 £ 2 £ 2 100.0 0.0
Vancomycin 0.5–2 1 1 100.0 0.0
Linezolid 0.25–2 2 2 100.0 –
Erythromycin 0.12 – > 8 0.5 > 8 65.9 33.6
Clindamycin £ 0.06 – > 8 0.12 > 8 74.1 25.9
Quinupristin–dalfopristin £ 0.25–1 0.5 0.5 100.0 0.0
Oxacillin £ 0.06 – > 2 0.5 > 2 73.3 26.7
Ceftriaxone 0.5 – > 32 4 > 32 73.1 24.8
Ciprofloxacin 0.06 – > 4 0.25 > 4 70.7 28.9
Tetracycline £ 2 – > 8 £ 2 > 8 83.2 15.9
Trimethoprim–sulphamethoxazole £ 0.5 – > 2 £ 0.5 > 2 84.3 15.7
Coagulase-negative staphylococci (251)b
Dalbavancin £ 0.008–1 0.03 0.12 – –
Teicoplanin £ 2 – > 16 £ 2 8 92.4 2.0
Vancomycin 0.25–4 1 2 100.0 0.0
Linezolid 0.5–2 1 1 100.0 –
Erythromycin £ 0.06 – > 8 > 8 > 8 40.2 59.8
Clindamycin £ 0.06 – > 8 0.12 > 8 58.6 41.0
Quinupristin–dalfopristin £ 0.25–2 £ 0.25 0.5 99.6 0.0
Oxacillin £ 0.06 – > 2 > 2 > 2 23.1 76.9
Ceftriaxone £ 0.25 – > 32 8 > 32 50.2 15.9
Ciprofloxacin 0.06 – > 4 0.5 > 4 57.4 38.6
Tetracycline £ 2 – > 8 £ 2 > 8 79.6 19.6
Trimethoprim–sulphamethoxazole £ 0.5 – > 2 2 > 2 55.4 44.6
b-Haemolytic streptococci (53)c
Dalbavancin £ 0.008–0.06 £ 0.008 0.06 – –
Teicoplanin £ 2 £ 2 £ 2 – –
Vancomycin 0.25–1 0.25 0.5 100.0 –
Linezolid 0.25–1 1 1 100.0 0.0
Erythromycin £ 0.06–2 £ 0.06 £ 0.06 98.1 1.9
Clindamycin £ 0.06–0.12 £ 0.06 £ 0.06 100.0 0.0
Quinupristin–dalfopristin £ 0.25–0.5 £ 0.25 0.5 100.0 0.0
Penicillin £ 0.016–0.12 £ 0.016 0.06 100.0 –
Ceftriaxone £ 0.25 £ 0.25 £ 0.25 100.0 –
Levofloxacin 0.12–1 0.5 0.5 100.0 0.0
Tetracycline £ 2 – > 8 £ 2 > 8 58.5 41.5
Trimethoprim–sulphamethoxazole £ 0.5–2 £ 0.5 £ 0.5 – –
Viridans group streptococci (13)d
Dalbavancin £ 0.008–0.03 0.016 0.016 – –
Teicoplanin £ 2 £ 2 £ 2 – –
Vancomycin 0.25–1 0.5 1 100.0 –
Linezolid 0.5–1 1 1 100.0 –
Erythromycin £ 0.06–2 £ 0.06 1 73.3 20.0
Clindamycin £ 0.06 £ 0.06 £ 0.06 100.0 0.0
Quinupristin–dalfopristin £ 0.25–1 0.5 0.5 100.0 0.0
Penicillin £ 0.016–8 0.06 4 53.3 20.0
Ceftriaxone £ 0.25–8 £ 0.25 2 86.7 6.7
Levofloxacin 0.5–4 1 4 86.7 0.0
Tetracycline £ 2 – > 8 £ 2 > 8 73.3 26.7
Trimethoprim–sulphamethoxazole £ 0.5 – > 2 £ 0.5 > 2 – –
Streptococcus pneumoniae (208)
Dalbavancin £ 0.008–0.06 0.016 0.016 – –
Teicoplanin £ 2 £ 2 £ 2 – –
Vancomycin £ 0.12–0.5 0.25 0.5 100.0 –
Linezolid 0.12–2 1 1 100.0 –
Erythromycin £ 0.25 – > 8 £ 0.25 8 84.5 15.0
Clindamycin £ 0.25 – > 8 £ 0.25 £ 0.25 95.1 4.9
Quinupristin–dalfopristin 0.5–1 £ 0.5 £ 0.5 100.0 0.0
Penicillin £ 0.03 – > 4 £ 0.03 2 73.1 13.9
Ceftriaxone £ 0.008–2 0.12 1 99.5 0.0
Levofloxacin 0.25–2 1 2 100.0 0.0
Tetracycline £ 2 – > 8 £ 2 > 8 86.1 12.0
Trimethoprim–sulphamethoxazole £ 0.5 – > 2 £ 0.5 > 2 57.7 30.3
Enterococci (157)e
Dalbavancin £ 0.008 – > 16 0.03 0.12 – –
Teicoplanin £ 2 – > 16 £ 2 £ 2 95.5 3.8
Vancomycin 0.5 – > 16 2 2 94.3 4.5
Linezolid 1–2 2 2 100.0 0.0
Quinupristin–dalfopristin £ 0.25 – > 2 > 2 > 2 10.2 81.5
Ampicillin £ 1 – > 16 2 16 89.8 10.2
Chloramphenicol £ 2 – > 16 8 > 16 71.3 26.8
Gentamicin (HL) £ 500 – > 1000 £ 500 > 1000 66.4 33.6
Streptomycin (HL) £ 1000 – > 2000 £ 1000 > 2000 72.6 27.4
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were inhibited at lower dalbavancin concentra-
tions than penicillin-susceptible isolates
(0.06 mg ⁄L; Table 2). Against 53 b-haemolytic
streptococcal isolates, dalbavancin (MIC50,
£ 0.008 mg ⁄L) was highly active and exhibited
greater activity than vancomycin (MIC50,
0.25 mg ⁄L) and linezolid (MIC50, 1 mg ⁄L). This
group of organisms was susceptible to most
antimicrobial agents, except tetracycline (58.5%
susceptible) and erythromycin (98.1% suscept-
ible). In contrast, only 53.3% of streptococcal
isolates belonging to the viridans group were
susceptible to penicillin. Dalbavancin also
showed excellent in-vitro activity against this
group of streptococci, and inhibited all isolates
at £ 0.03 mg ⁄L.
Dalbavancin (MIC50, 0.03 mg ⁄L) was 64-fold
more potent than vancomycin (MIC50, 2 mg ⁄L)
and linezolid (MIC50, 2 mg ⁄L) against Enterococ-
cus spp. isolates. Most (86.6%) of the isolates were
E. faecalis, and were therefore mostly ampicillin-
susceptible and quinupristin–dalfopristin-resist-
ant. All vancomycin-susceptible Enterococcus spp.
were inhibited by £ 0.25 mg ⁄L dalbavancin.
Although vancomycin-non-susceptible Enterococ-
cus spp. isolates showed higher dalbavancin MIC
values (MIC50, 16 mg ⁄L), two isolates of Entero-
coccus spp. and one E. faecium isolate that exhib-
ited the VanC and VanB resistance phenotypes
were inhibited at dalbavancin concentrations
£ 0.12 mg ⁄L. Only VanA isolates were not inhib-
ited by low concentrations of dalbavancin.
Dalbavancin was also very active against
uncommonly isolated Gram-positive organisms
such as Corynebacterium spp., Listeria spp., and
Micrococcus spp. (Table 3). Against Listeria spp.
and Corynebacterium spp., the dalbavancin MICs
ranged from 0.03 to 0.12 mg ⁄L. Lower MICs
(0.016 mg ⁄L) were observed for two isolates of
Micrococcus spp.
DISCUSSION
Vancomycin and teicoplanin are still the only
glycopeptide antibiotics available for use in man.
Emergence of resistance in enterococci and sta-
phylococci has led to increasing restriction of their
use to treatment of severe infections caused by
Gram-positive bacteria for which no alternative
agents are acceptable (because of resistance or
allergy). Considerable efforts have been made to
produce semi-synthetic glycopeptides, such as
dalbavancin, with improved pharmacokinetic and
pharmacodynamic properties, and with activity
against resistant strains [5,17]. In the present
Table 2. Influence of various resistance profiles on the
MICs of dalbavancin against 1152 isolates from Latin
American medical centres
Organism
Resistance phenotype
(no. tested)
Dalbavancin MICs (mg/L)
Range 50% 90%
Staphylococcus aureus Oxacillin-susceptible (393) £ 0.008–0.25 0.06 0.06
Oxacillin-resistant (143) 0.016–0.12 0.06 0.06
Coagulase-negative
staphylococci
Oxacillin-susceptible (58) £ 0.008–0.12 0.03 0.06
Oxacillin-resistant (193) £ 0.008–1 0.03 0.12
Streptococcus
pneumoniae
Penicillin-susceptible (152) £ 0.008–0.06 0.016 0.016
Penicillin-intermediate (27) £ 0.008–0.06 0.016 0.016
Penicillin-resistant (29) £ 0.008–0.016 0.016 0.016
Enterococci Vancomycin-susceptible (148) £ 0.008–0.25 0.03 0.06
Vancomycin-resistant (9) 0.06 to > 16 16 –
Table 1. Continued
Organism ⁄ antimicrobial (no. tested)
MIC (mg/L) Percentage by categorya
Range 50% 90% Susceptible Resistant
Ciprofloxacin 0.5 – > 4 1 > 4 54.1 38.2
Tetracycline £ 2 – > 8 > 8 > 8 32.5 67.5
Trimethoprim–sulphamethoxazole £ 0.5 – > 2 £ 0.5 > 2 – –
aSusceptibility interpretations according to NCCLS criteria [16].
bIncludes S. auricularis (one isolate), S. capitis (one), S. epidermidis (46), S. haemolyticus (16), S. hominis (six), S. lugdunensis (one), S. saprophyticus (six), S. simulans (two), S. warnerii
(five) and unspeciated (167).
cIncludes group A (33 isolates), group B (15), group C (3), group G (1) and unspeciated (1).
dIncludes Strep. anginosus (one isolate), Strep. mitis (five), Strep. oralis (one), Strep. salivarius (one), Strep. sanguis (two) and unspeciated (three).
eIncludes: E. avium (one isolate), E. faecalis (136), E. faecium (16), E. gallinarum (one), E. hirae (one) and Enterococcus spp. (two).
HL, high-level resistance; indicates that no criteria have been established.
Table 3. In-vitro activity of dalbavancin against uncom-
monly isolated Gram-positive organisms
Organism (no. tested)
Cumulative percentage inhibited at MIC (mg/L)
£ 0.008 0.016 0.03 0.06 0.12 0.25
Corynebacterium spp. (3)a 0 0 2 0 1 0
Listeria spp. (6)b 0 0 1 2 3 0
Micrococcus spp. (2) 0 2 0 0 0 0
aIncludes C. afermentans (two isolates) and C. jeikeium (one).
bIncludes L. monocytogenes (two isolates) and unspeciated (four).
98 Clinical Microbiology and Infection, Volume 11 Number 2, February 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 95–100
study, dalbavancin showed excellent in-vitro
activity against staphylococci, streptococci and
vancomycin-susceptible enterococci isolated from
patients in Latin America. As found in previous
studies [10,11,18], dalbavancin activities against
these Gram-positive pathogens, including methi-
cillin-resistant staphylococci, penicillin-resistant
pneumococci and viridans streptococci, and
multiresistant organisms, was superior to those
of vancomycin, teicoplanin, quinupristin–dalfopr-
istin and linezolid (Table 1). The present study
also demonstrated excellent activity of dalbavan-
cin against uncommonly isolated bacteria such as
Listeria spp. and Corynebacterium spp., which is
also consistent with previous reports [12,18].
Dalbavancin showed decreased activity against
vancomycin-resistant Enterococcus spp. possessing
the VanA phenotype [10,11,18]. In Latin America,
most vancomycin-resistant Enterococcus isolates
belong to the species E. faecalis and carry vanA.
Fortunately, the rates of vancomycin resistance
among enterococci isolated from this geograph-
ical region were < 5.0%, and most vancomycin-
resistant Enterococcus isolates remain susceptible
to ampicillin [4,19].
Although no glycopeptide-intermediate S. au-
reus isolate was found in this study, emergence
of glycopeptide-intermediate S. aureus has been
reported previously in Latin America [20]. In
addition, there has been a preliminary report of
linezolid resistance in MRSA isolated from Bra-
zilian cystic fibrosis patients [21]. Thus, antimi-
crobial agents active against strains with these
phenotypes of resistance are desirable. Dalba-
vancin has shown superior potency to conven-
tional glycopeptides in animal models of
endocarditis caused by MRSA, with and without
reduced susceptibility to vancomycin and tei-
coplanin [10,13]. In addition, in the rat granulo-
ma pouch infection model, dalbavancin
demonstrated greater efficacy than vancomycin
or linezolid against methicillin-susceptible or
methicillin-resistant S. aureus, even when it was
administrated less frequently and at lower dos-
ages than the comparators [22]. Dalbavancin has
also been effective in models of penicillin-sus-
ceptible and penicillin-resistant pneumococcal
pneumonia in immunocompetent and neutrop-
enic rats [10].
In phase 1 studies in man, dalbavancin was
well-tolerated, and bactericidal activity persisted
in human plasma for 7 days after an intravenous
dose of 500 mg [23]. Given the long dalbavancin
half-life, single doses of ‡ 500 mg maintained
concentrations above the minimal bactericidal
level for at least 1 week [23]. A recent phase II
clinical study demonstrated that a once-weekly
dose of dalbavancin was successful for the treat-
ment of deep skin and soft tissue infections [14],
and dalbavancin was found to be as effective as
the standard practice comparators (clindamycin,
ceftriaxone, vancomycin or cefazolin) [14].
In conclusion, the present study showed that
dalbavancin has potent in-vitro activity against
important Gram-positive bacteria isolated from
Latin American patients, similar to results des-
cribed for bacteria from other diverse geographical
areas. Its antimicrobial potency, pharmacokinetic
properties and tolerability in patients mean that
dalbavancin could represent an important thera-
peutic option against infections caused by Gram-
positive cocci, excluding those caused by entero-
cocci with the VanA phenotype.
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